Ebola Drug ZMapp mightn’t be as efficient as thought: study

Ebola Drug ZMapp mightn’t be as efficient as thought: study

Experimental Ebola drug ZMapp might not be as efficient in saving lives of Ebol patients as many believe, a new study cautioned.

ZMapp was one of the most sought-after and promising treatments for treating Ebola during the 2014 outbreak. But, results of the new study suggested that the drug might not be very helpful in treating the deadly illness.

Rather than providing a precise answer to whether ZMapp can really saves Ebola patients' lives, the results of the study are somewhat inconclusive and anticlimactic.

The researchers found that a smaller percentage of people treated with ZMapp died as compared with those who did not get the treatment. But they also found that the difference could have been due chance. In other words, the difference wasn't "statistically" significant.

In the Oct. 13th issue of the New England Journal of Medicine, the researchers wrote, "The laudable and rapid decline in eligible new cases of [Ebola virus disease] was a factor that no trial design could anticipate, and it affected our ability to reach definitive conclusions … the outbreak appears to have ended with no incontrovertible evidence."

The Ebola epidemic killed more than 11,000 people and made more than 28,000 sick between 2014 and 2016.

The Ebola virus causes severe internal bleeding, organ failure and can gradually lead to death. It spreads from an infected person to a healthy person through contact with bodily fluids like blood. Symptoms include fever, chills, headache, muscle pain and internal bleeding resulting in vomiting or coughing blood.